The 12 analysts offering 12-month price forecasts for Intra-Cellular Therapies Inc have a median target of 77.50, with a high estimate of 100.00 and a low estimate of 59.00. The median estimate represents a +42.86% increase from the last price of 54.25.
The current consensus among 13 polled investment analysts is to Buy stock in Intra-Cellular Therapies Inc. This rating has held steady since August, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.61
Reporting Date Nov 07
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.